Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00704483 · ClinicalTrials.gov registry record · Phase 2
Efficacy of SBR759 in Lowering Serum Phosphate Levels in Chronic Kidney Disease Patients on Hemodialysis
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 321
- Enrollment target
NCT00704483 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 321 participants.
The verdict
NCT00704483, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 321 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy of SBR759 compared to sevelamer HCl in lowering serum phosphate levels in Chronic Kidney Disease patients on hemodialysis
Interventions
- DRUG SBR759
- DRUG Sevelamer HCl
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 321 participants |
| Start Date | 2008-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00704483
The ClinicalTrials.gov registry entry for NCT00704483 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 321 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which SBR759 is the first listed.
NCT00704483 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00704483 about?
NCT00704483 is a clinical study titled "Efficacy of SBR759 in Lowering Serum Phosphate Levels in Chronic Kidney Disease Patients on Hemodialysis". This study will evaluate the efficacy of SBR759 compared to sevelamer HCl in lowering serum phosphate levels in Chronic Kidney Disease patients on hemodialysis
What is the current status of trial NCT00704483?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 321 participants. The study started on 2008-07.
What interventions are being tested in trial NCT00704483?
The interventions under investigation include: SBR759 (DRUG), Sevelamer HCl (DRUG).
Who is sponsoring clinical trial NCT00704483?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.